Previous 10 | Next 10 |
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications,...
NIO (NYSE: NIO ) -20% on Q4 earnings . More news on: NIO, SELLAS Life Sciences Group, Inc., Qutoutiao, Stocks on the move, Read more ...
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications,...
FTE Networks (NYSEMKT: FTNW ) +223% on $116M contract . More news on: FTE Networks, Inc., Heat Biologics, Inc., Zynerba Pharmaceuticals, Stocks on the move, Read more ...
Phase 1/2 basket trial of lead clinical candidate, galinpepimut-S (GPS), plus Keytruda ® (pembrolizumab) ongoing; Phase 3 registrational study for GPS monotherapy in acute myeloid leukemia (AML) planned Discussions on development path for nelipepimut-S (NPS) ongoing with ...
The following slide deck was published by SELLAS Life Sciences Group, Inc. in conjunction with this Read more ...
SELLAS Life Sciences (NASDAQ: SLS ) updates on two pipeline programs: More news on: SELLAS Life Sciences Group, Inc., Merck & Co Inc., Roche Holding Ltd ADR, Healthcare stocks news, Stocks on the move, Read more ...
Dr. Richard Maziarz and Dr. Roisin O'Cearbhaill Named Co-Principal Investigators for Galinpepimut-S (GPS) – Pembrolizumab Phase 1/2 Basket Trial Immune Response Data from the Phase 2b Nelipepimut-S (NPS) plus Trastuzumab Combination Study Demonstrates Antigen-Specific T-cell Cl...
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, ...
Oppenheimer says small- to mid-cap biotech stocks could have more downside risk going into the new year after this quarter's pullback while the historically low valuations for large-cap companies could reach the lowest point. More news on: Regeneron Pharmaceuticals, Inc., Alexion Pharmaceu...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...